Sexually transmitted human papillomavirus (HPV) infections cause most cervical cancers. The inability to propagate HPV in vitro has led to the development of alternative approaches to antigen production for vaccine development. In the present work we describe a low-cost efficient production of HPV virus-like particles (VLPs) in a non-fermentative system based on 
Introduction
Human papillomavirus (HPV) is recognized as the main causative agent of invasive carcinomas of the uterine cervix (Sigurdsson et al., 2007) . Cervical cancer is the most common cancer affecting women in developing countries, where 80% of deaths caused by this type of cancer occur. Among other considerations, affordability and cost-effectiveness of vaccination are the most important factors for application of HPV vaccines in developing countries. Two HPV types, HPV16 and HPV18, account for 60-70% of all cervical cancer cases worldwide (Ho et al., 1998; Munoz et al., 2003) . The inability to propagate HPV in vitro has led to the development of alternative approaches to antigen production for vaccine development (Carter et al., 1991; Rose et al., 1993; Xi and Banks, 1991) . Successful development of papillomavirus vaccines is dependent upon the use of nondenatured, conformationally correct capsid antigens forming pentamers or VLPs (Bonnez, Rose, and Reichman, 1992; Christensen et al., 1992) .
The viral capsid is primarily composed of 72 pentamers (capsomers) of the major late L1 protein, in association with 12 or more copies of the L2 protein.
The L1 pentamers have the intrinsic property of self-assembly into empty capsids, referred to as virus like particles (VLPs) (Hagensee, Yaegashi, and Galloway, 1993; Kirnbauer et al., 1992; Kirnbauer et al., 1993; Rose et al., 1994; Zhou et al., 1993) . VLPs are structurally and immunologically similar to infectious viruses, as determined by electron microscopy and their ability to bind conformation-dependent monoclonal antibodies (mAbs) (Kirnbauer et al., 1992) .
Conformational epitopes have been identified on the surface of HPV L1 VLPs . It is now well established that those epitopes are responsible for the activity of neutralizing antibodies (Christensen et al., 1994; White et al., 1998; White et al., 1999) and it has been demonstrated that high levels of neutralizing antibodies can be generated after immunization with HPV VLPs (Harro et al., 2001) . In recent years, biotechnology has provided for the tools that allow the use of living organisms to produce recombinant vaccines with high efficiency but at a very low production costs. One of these alternatives is the use of insects as bioreactors (Liu, DeCarolis, and Beek, 2007) . Recently, It has been described the obtention of rotavirus VLPs from infected Spodoptera frugiperda larvae using baculovirus, opening the option to get vaccines against rotavirus from insect larvae (Molinari, Peralta, and Taboga, 2008) . There are other examples of recombinant subunit vaccines against infectious agents obtained from insects used as bioreactors (Chimeno Zoth et al., 2009; Hu, Yao, and Wu, 2008; Johansson, Price, and Kilbourne, 1995; Matsuoka et al., 1996; Pang et al., 2002) . We currently have in clinical studies an insect larvae-derived recombinant subunit vaccine against RHDV (Perez-Filgueira et al., 2007) .
Our main goal in this work was to exploit all possibilities of insects as biofactories to produce an effective HPV vaccine, always thinking in a dramatic reduction of production costs. In the present study we describe the expression of the L1 protein from HPV type 16 in Trichoplusia ni larvae. L1 protein self-assembled forming VLPs in the larvae tissues and the immune response of larva-derived VLPs compared to that induced by VLPs obtained in insect cell cultures in immunized mice was similar.
Experimental procedures

Construction of the Baculovirus expression vector
HPV-16 L1 cDNA (GenBank Accession AF472508) was provided by Dr. 
Larvae and insect cell infection
Trichoplusia ni (T. ni, Cabbage looper) larvae were reared under level-2 biosafety conditions following previously described methodology (PerezFilgueira et al., 2006) . For all experiments, fifth-instar larvae were injected with the recombinant baculoviruses near the proleg (forward the body cavity) using 
Larvae
For extraction of larvae VLPs, 500 mg of fresh weight larvae were homogenized in a blender with 8 mL of PBS-HS and sonicated for 2 min. After centrifugation at 20000 g for 5 min at 4ºC, supernatants were layered onto a 40% sucrose cushion. The rest of the protocol was similar to that used for insect cell VLP extraction.
Electron microscopy and immunogold labelling
For negative staining, 20 µL of samples of the positive fractions in the CsCl gradient were dialyzed against PBS-HS on floating filter pads (0.2 µm pore size, Millipore). Samples were placed onto carbon-coated copper grids (400 mesh size) covered with Formvar membrane and stained with 1% uranyl acetate solution for 1 min. Samples were inspected under a ZEISS EM 910 transmission electron microscope (TEM) operating at 60 and 80 kV.
Analysis of L1 assembly by sucrose sedimentation
To identify different assembly forms of L1, soluble extracts from insect cells and larvae (200 mg/ 2mL PBS-HS) were prepared as previously described for western blotting. Samples were loaded onto linear 10 to 65% (w/v) sucrose gradients. After 2 h centrifugation at 150000 g in a swinging bucket rotor, 20
fractions of 500 µL were collected, determined their density by refractometry and analysed by ELISA with the Cam Vir-1 (Abcam) antibody. Sedimentation of L1 capsomers was calibrated with catalase from bovine liver (Sigma) as sedimentation marker (11.3S).
Immunization of animals
Female Balb/c mice were purchased from Harlan Ibérica (Barcelona, Spain).
Groups of 8-week-old mice (n= 6) were immunized by intraperitoneal injection (0.2 mL) with CsCl purified VLPs from larvae (as described before) in presence of complete Freund's adjuvant. The amount of VLPs injected was 5 µg per mouse. As a negative control, a group of mice (n= 6) was intraperitoneally immunized with larvae extracts from BacNi (baculovirus with no insert) infected larvae as negative control. As a positive control, a group of mice (n= 6) was intraperitoneally immunized with 5 µg of VLPs from insect cell cultures purified by CsCl. Animals were boosted at days 21 and 35 (using incomplete Freund's Adjuvant). Blood samples were collected from the facial vein at days 0, 21, 35
and 50. Pooled sera were titrated against purified VLPs produced in yeast (Gardasil, Merck) by ELISA in microtitre plates coated overnight at 4ºC with 50 µL of yeast-derived VLPs (100 ng of L1-VLPs per well) diluted in PBS (pH 7.4).
Subsequently, the wells were blocked 1 h at room temperature with PBS-TM and then incubated 1 h at 37ºC with serial dilutions of pooled sera in PBS-TM.
Then, plates were incubated for 1 h at 37ºC with a goat anti-mouse IgG antibody horseradish peroxidase conjugate. Washes were performed between each step with PBS-T. Plates were developed by adding ABTS. Absorbance at 405 nm was measured in a microtiter plate reader. Antibody titres were expressed as the highest serum dilution to yield twice the absorbance mean of pre-immune sera.
Results
Expression of HPV-16 L1 in Sf-21 cells and insect larvae
HPV-16 L1 ORF was cloned into the baculovirus transfer vector pFasBac giving the plasmid named pL1, which was used to obtain a recombinant baculovirus (BacL1) as described in Methods. To study the expression of the L1 protein in T. ni insect larvae, SDS-PAGE of soluble and insoluble protein larvae fractions was made using as a control an insect cell His-tag L1 protein purified by affinity chromatography. Coomassie blue-stained gels showed that L1 was easily identified as a major band with mobility around 55 kDa (Fig. 1a) . Most L1
protein was detected in the soluble fraction with identical mobility to that observed with L1 protein expressed in insect cells. The specificity of the expressed protein was further characterized by western blot using the Cam Vir-1 antibody (Fig. 1b) .
Once the L1 expression was demonstrated, the optimal L1 expression conditions induced by BacL1 in larvae were analized.. Fifth instar larvae were inoculated with three different doses of BacL1 virus. Samples were processed at different times post-inoculation and analyzed by western blot. A 55 KDa band corresponding to the L1 protein was accumulated in inoculated larvae in a timedependent manner (Fig. 1c) . A specific ELISA quantification also confirmed these observations (Fig. 1c) , determining optimal conditions for L1 expression with an infection dose of 4 x 10 4 -10 5 pfu/larva at 72 hpi. At later post-inoculation time the larvae productivity use to drop dramatically.
In order to determine the larvae expression efficiency we compared it with the insect cell commercial system and a recently described method of chloroplast transformation of tobacco for L1 vaccine production (Fernandez-San Millan et al., 2008) was carried out. As it is shown in figure 1d , the L1 recombinant protein reached accumulation levels ranging from 18 to 21 mg per g of insect biomass (about four insect larva). Insect larvae produced about 2.5 and 5 times more L1 protein than insect cell cultures and transgenic chloroplasts respectively per biomass unit. Therefore, insect larvae are the most efficient expression system for L1 protein described to date.
Characterization of larvae produced virus-like particles.
Since a successful development of a papilloma vaccine is dependent upon conformationally correct capsid antigens forming pentamers or VLPs, we investigated the L1 self-assembling in larvae tissues. For that purpose, total soluble protein fractions obtained from BacL1-infected larvae were used for HPV VLPs purification using CsCl and sucrose gradients. A clear antigenic peak measured by ELISA, using the Cam Vir-1 anti-L1 mAb as primary antibody, was detected in the fraction 4, collected from the CsCl gradient both with material derived from insect cell cultures or insect larvae (Fig. 2a) . L1
protein was mainly present in CsCl gradient fractions at a density of 1.27 g/mL,
suggesting the presence of VLPs. In both systems the peaks of L1 protein derived from insect cells and larvae overlapped indicating that complex structures were very similar in densities (Fig. 2a) . Fractions where the maximum L1 was found either in cells or in larvae extracts were also positive in immunoblot assay (Fig. 2b) .
Analysis of fraction 4 of the CsCl gradient by electron microscopy using negative staining showed structures that correspond in shape and size to previously described HPV VLPs. They consisted of spherical particles of about 55 nm in diameter with a regular array of capsomeres. Smaller, larger, and irregular spheres as well as tubular structures were also seen (Fig. 2c ). These structures have been already described by others in plants (Biemelt et al., 2003; Maclean et al., 2007) but also in insect cells (Le Cann et al., 1995; Volpers et al., 1994) .
Soluble proteins from infected larvae and insect cell cultures were also submitted to sucrose sedimentation analysis in order to address L1 selfassembly patterns. Gradient fractions were collected and analyzed by ELISA with the Cam Vir-1 mAb. Results revealed that the L1 antigen assembled into similar structures independently of the production method used (insect cell cultures or larvae), presenting overlapping peaks of L1 distribution at specific sucrose densities measured by refractometry (Fig. 2d) . Either there were not capsomers in fraction 17 nor monomers in fraction 20.
Immunogenicity of purified HPV 16 VLPs produced in insect larva
To investigate the immunogenicity of larvae-derived HPV VLPs, mice (5 Balb/c per group) were intraperitoneally immunized with 5 µg of purified VLPs derived from larvae and the immune response was compared to that induced by similar preparations derived from Sf-21 insect cells. Animals were boosted at days 21 and 35 after the first vaccine dose. The L1-specific humoral responses in mice were analyzed by L1 VLPs-based ELISA using native yeast-derived VLPs as antigen to coat the plates (Fig. 3) . At day 50 post inoculation, all immunized animals reached titres higher than 1/10000. In the case of the animals immunized with the purified VLPs from larvae the titres were even higher than those derived from mice immunized with insect cells derived VLPs (Fig. 3) . All control mice immunized with extracts from infected larvae with a non-related baculovirus and equally processed did not show any specific immune response cross-reactive with L1 protein (Fig. 3) . The major structural protein of the HPV capsid, L1, is the antigen of choice for the development of prophylactic vaccines. It is well known that expression of the L1 by recombinant baculoviruses in insect cell cultures is sufficient for the formation of VLPs which are highly immunogenic (Rose et al., 1993) .
Discussion
Interestingly one of the two approved prophylactic HPV vaccines is expressed in insect cell cultures by fermentation technology by recombinant baculoviruses (Cervarix). However, although this technology platform is very efficient in recombinant protein production and generates highly immunogenic selfassembled L1 derived VLPs, the production costs increase the vaccine price at levels that can not be easily applied for HPV prevention programs in developing countries. To overcome this problem, other heterologous systems to produce L1 have been developed as bacteria, eukaryotic cell cultures or transgenic plants (Aires et al., 2006; Fernandez-San Millan et al., 2008; Fraillery et al., 2007; Heino, Dillner, and Schwartz, 1995; Kim et al., 2007; Maclean et al., 2007) .
However, none of them allow a significant cost reduction that would boost its wide use in developing countries.
It has been extensively demonstrated that the larvae expression system is a suitable method for inexpensive production of large amounts of recombinant proteins for either vaccine or diagnostic use (Barderas et al., 2000; Ferrer et al., 2007; Gomez-Sebastian et al., 2008; Lopez et al., 2005; Perez-Filgueira et al., 2006; Perez-Filgueira et al., 2007) . In this work we have demonstrated the high yield production of L1 protein in T. ni larvae that self-assembles forming the same type of VLPs that are currently used in vaccine formulations against this important infectious disease. One gram of infected insect biomass is able to produce in optimal conditions 18-21 mg of totally soluble recombinant L1 protein This means a 2.5 times the L1 production yields obtained in insect cell cultures and 5 times more productivity than transplastomic tobacco plants per biomass unit (Fernandez-San Millan et al., 2008) . Another interesting feature of the insect platform technology is that the system requires lower amounts of baculovirus inocula than the insect cell cultures for protein expression optimization. This is of great interest from a practical point of view since the production cost of the baculovirus stocks could be also reduced. Furthermore, the necessity to generate high titre virus stocks and the difficulty to get them would be also avoided with the larvae expression system. Additionally, recombinant baculoviruses can be propagated in insect larvae without the need of insect cell cultures avoiding any possibility of the use of any animal compound (ie. animal sera) in the production process.
The reactivity of the larva-derived L1 structures with the conformational-specific anti-HPV antibody H16.V5 mAb, strongly suggest a correct conformation of the HPV VLPs generated in the larva system. Additionally, the data obtained from CsCl or sucrose sedimentation gradients related to sedimentation coefficient of L1 structures obtained from larva, as well as the electron microscopy observations, corroborates that VLPs formed are similar to that obtained by other vaccine production systems. As L1 protein expressed in insect cells, L1
obtained by infected larvae was present in CsCl gradient fractions at a density of 1.27 g/mL, in which it is known that HPV VLPs migrates. In addition, as observed by sucrose gradient sedimentation, L1 structural pattern found in larva overlaps with that obtained in insect cell cultures. Electron microscopy negative staining of sedimentation fractions revealed also the presence of indistinguisible
VLPs to that produced in insect cell cultures (Fig. 2c ).
Mice immunized with HPV VLPs derived from larva or insect cell cultures
showed very good humoral immune responses, with antibody titers higher than 1/10000 after two vaccine boosts. Up to date, capsomers are considered to be a cost-effective alternative to VLP-based vaccines because they can be produced in bacterial expression systems and because of their high degree of stability. However, it has been already demonstrated that VLPs induced, independently of the route of immunization, significantly higher titers of neutralizing antibodies than capsomers (Fligge et al., 2001 ). The insect expression system is a very competitive alternative to bacterial expression systems in terms of production costs, with the advantage of the insect cells in terms of facilitate high complex structures formation such L1 VLPs instead only capsomers as those produced in bacteria systems.
For countries with a gross domestic product of less than $1000 per capita, the per-dose cost may need to be as low as $1 to $2 to make vaccination both costeffective and affordable (Agosti and Goldie, 2007) . Without a doubt, one of the greatest barriers to the introduction of this vaccine is price. Using the larvae expression system, the high production costs of current HPV vaccines would be dramatically reduced, allowing their distribution in developing countries, where the highest incidence of this disease occurs. It is important to remark that with every 5-year delay in bringing vaccination to developing countries, 1.5 million to Another concern is that by eliminating the two major oncogenic HPV genotypes through vaccination, current HPV vaccines target only two oncogenic types (albeit those responsible for 70% of cervical cancers), the remaining oncogenic types will become more common to fill a niche previously occupied by HPV16
and HPV18, thereby reducing the impact of the current vaccines on cervical cancer. However a low-cost multivalent HPV vaccine eliciting protection against a broad spectrum of HPV types would be particularly useful where national screening programs are currently not instituted. Our approach could be the clue to afford the challenge of a viable worldwide vaccination because its simplicity, easily testing and manufacture of such complex vaccines at a low cost. The scalability of vaccine production in the larva platform is immediate. In less than 5 weeks it is possible to generate a new recombinant baculovirus and initiate a massive production in larva without minor optimization procedures.
Figures
Figure 1 are the result of two repetitions.
